Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2024; 30(3): 280-282
Published online Jan 21, 2024. doi: 10.3748/wjg.v30.i3.280
Use of curcumin and its nanopreparations in the treatment of inflammatory bowel disease
Zi-Wen Meng, Bing Chang, Li-Xuan Sang
Zi-Wen Meng, Li-Xuan Sang, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
Bing Chang, Department of Gastroenterology, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: Meng ZW wrote the letter; Chang B and Sang LX supervised the manuscript draft; all authors contributed important intellectual content during drafting and revising of the manuscript.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Xuan Sang, MD, PhD, Professor, Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Province, China. sanglixuan2008@163.com
Received: October 6, 2023
Peer-review started: October 6, 2023
First decision: December 6, 2023
Revised: December 12, 2023
Accepted: January 4, 2024
Article in press: January 4, 2024
Published online: January 21, 2024
Processing time: 103 Days and 16.6 Hours
Core Tip

Core Tip: Curcumin (CUR) can efficiently decrease the activity of proinflammatory cytokines by communicating with transcription factors and signaling molecules. It is a new area of research that may be promising in the future to treat patients with inflammatory bowel disease, especially in patients with ulcerative colitis. How to improve the bioavailability of CUR in vivo was also discussed.